Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

Virginia Tech researcher receives $2.2 million to advance study on small 'fat burning' molecules

The liver is the most resilient organ in the human body. It can remove toxins from the bloodstream, recycle red blood cells, maintain sugar levels, and it can even regenerate itself. But, when a large amount of fat builds up in the liver, it becomes too inflamed to perform its crucial duties.

14 Jun 2021

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

Enterprise Therapeutics Ltd today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD001.

14 Jun 2021

British Liver Trust calls for action to address rising obesity rates that fuel liver disease crisis

The British Liver Trust is calling for greater awareness of a silent yet serious form of fatty liver disease, non-alcohol related steatohepatitis (NASH), as one million adults were reported to have been admitted to hospital with obesity-related conditions in 2020.

14 Jun 2021

PET radiotracer can noninvasively identify and monitor pulmonary fibrosis

Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.

13 Jun 2021

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Researchers in the United States and Canada have identified DNA on/off “switches” within the angiotensin-converting enzyme 2 (ACE2) gene that may control the expression of this host cell receptor before, during and after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

9 Jun 2021

Microgel-coated mesenchymal stromal cells can reverse pulmonary fibrosis

Researchers at the University of Illinois Chicago have shown that even after lung tissue has been damaged, it may be possible to reverse fibrosis and promote tissue repair through treatment with microgel-coated mesenchymal stromal cells.

9 Jun 2021

Natural products show promise against COVID-19 via iron chelation

Researchers at the University of Catania in Italy investigated whether natural compounds could prevent disease progression. Their study published in the Journal of Clinical Medicine found that iron chelators and protease inhibitors can counteract SARS-CoV-2 infection.

7 Jun 2021

UVA researchers discover potential treatment approaches for muscle loss in myotonic dystrophy type 1

University of Virginia School of Medicine researchers have identified new insights and potential treatment approaches for muscle loss in myotonic dystrophy type 1 (DM1), the most common form of muscular dystrophy.

7 Jun 2021

Study finds molecular pathway that can explain how chronic kidney disease induces heart failure

According to the Global Burden of Disease Study 2017, close to nine percent of the global population lives with some form of chronic kidney disease, or CKD. Not only does the condition affect renal function, CKD has long been associated with increased risk of cardiovascular disease.

5 Jun 2021

Could a green tea compound combat SARS-CoV-2?

Researchers recently published an article that reviewed the mechanisms by which EGCG could inhibit SARS-CoV-2 infection and the various syndromes caused by COVID-19.

3 Jun 2021

Long COVID patients at higher risk of small airway disease

The preprint discussed herein describes the effects of SARS-CoV-2 on lung structure and function in patients with long COVID.

2 Jun 2021

Antibiotics provide no benefit for patients with idiopathic pulmonary fibrosis, study finds

Doctors have hoped that antibiotics could benefit patients with chronic lung diseases, but a new study has found no benefit for patients with life-threatening idiopathic pulmonary fibrosis in preventing hospitalization or death.

2 Jun 2021

Mice study shows that Western diet can lead to NASH, liver fibrosis

Apart from lifestyle interventions, there are currently no approved treatments for NASH. A liver transplant is sometimes the only remedy.

2 Jun 2021

Can depression increase the likelihood of rapid kidney function decline?

In a recent study, the presence of depressive symptoms in normally healthy individuals was found to correlate with rapid kidney function decline.

1 Jun 2021

Shared genetic architecture between COVID-19 severity and other health conditions

Researchers in the United States have identified a shared genetic architecture between coronavirus disease 2019 (COVID-19) severity and other health conditions.

24 May 2021

New AI tool predicts the extent of chronic damage in the kidney

Chronic kidney disease (CKD) is caused by diabetes and hypertension. In 2017, the global prevalence of CKD was 9.1 percent, which is approximately 700 million cases.

24 May 2021

Researchers investigate link between the liver’s immune system composition and NASH pathology

Our livers work hard to perform an entire range of activities: helping us digest food, maintaining body temperature and serving as an important checkpoint of the immune system for everything that we eat.

24 May 2021

Decreasing activity of ZMPSTE24 protease with age and comorbidities may make elderly COVID-19 patients vulnerable

Studies have shown that circulating levels of PAI-1, the coagulation cascade activator, are considerably higher in COVID-19 patients with severe respiratory illness compared to patients with bacterial-sepsis and acute respiratory distress syndrome (ARDS). Hence the increase in PAI-1 levels is recognized as an early marker of endothelial dysfunction in COVID-19 patients.

23 May 2021

Fibrosis News and Research

Further Reading

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

Virginia Tech researcher receives $2.2 million to advance study on small 'fat burning' molecules

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

British Liver Trust calls for action to address rising obesity rates that fuel liver disease crisis

PET radiotracer can noninvasively identify and monitor pulmonary fibrosis

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Microgel-coated mesenchymal stromal cells can reverse pulmonary fibrosis

Natural products show promise against COVID-19 via iron chelation

UVA researchers discover potential treatment approaches for muscle loss in myotonic dystrophy type 1

Study finds molecular pathway that can explain how chronic kidney disease induces heart failure

Could a green tea compound combat SARS-CoV-2?

Long COVID patients at higher risk of small airway disease

Antibiotics provide no benefit for patients with idiopathic pulmonary fibrosis, study finds

Mice study shows that Western diet can lead to NASH, liver fibrosis

Can depression increase the likelihood of rapid kidney function decline?

Shared genetic architecture between COVID-19 severity and other health conditions

New AI tool predicts the extent of chronic damage in the kidney

Researchers investigate link between the liver’s immune system composition and NASH pathology

Decreasing activity of ZMPSTE24 protease with age and comorbidities may make elderly COVID-19 patients vulnerable

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News